Nikhil Prasad Fact checked by:Thailand Medical News Team Jun 26, 2026 1 hour, 40 minutes ago
Medical News: Scientists Find Vitronectin May Help Stop Harmful Alzheimer’s Protein Clumping
Researchers from PeopleBio Inc., Republic of Korea; Yonsei University College of Medicine and Yongin Severance Hospital, Republic of Korea; the Institute of Behavioral Sciences in Medicine at Yonsei University, Republic of Korea; the Yonsei Graduate Program in Cognitive Science, Republic of Korea; the University of Toronto, Canada; and Gachon University’s Bionano Application Research Center and Department of Bionano Technology, Republic of Korea have uncovered a surprising blood protein that may play a major role in the earliest stages of Alzheimer’s disease.
Scientists identify vitronectin as a blood protein that may help prevent harmful amyloid-beta clumping linked to early
Alzheimer’s disease
Their study identified vitronectin, a naturally occurring blood protein, as an important factor that helps prevent toxic amyloid-beta proteins from sticking together. When vitronectin levels fell, harmful protein clumps formed more easily, potentially reflecting the early biological changes linked to Alzheimer’s disease.
A New Clue Hidden in the Blood
Alzheimer’s disease is widely known for the buildup of amyloid-beta proteins inside the brain. However, scientists have increasingly discovered that changes occurring in the blood may also mirror what is happening inside the brain years before memory problems become obvious.
Instead of measuring the amount of amyloid-beta already present, the researchers examined how easily these proteins formed toxic clusters, a process known as amyloid-beta oligomerization. Blood samples from individuals with amyloid-positive brain scans showed almost twice the tendency to form these harmful protein clusters compared to those without detectable brain amyloid.
The investigators also found that removing albumin and the network of proteins naturally attached to it completely erased this difference, suggesting that this protein network plays a crucial role in regulating amyloid behavior in the bloodstream.
Vitronectin Emerges as the Key Protective Protein
Using advanced protein analysis, the scientists examined hundreds of blood proteins associated with albumin. They discovered widespread disruption of this protein network in people with evidence of Alzheimer’s pathology.
Among all the altered proteins, vitronectin stood out as one of the most important. Blood levels of vitronectin were approximately 39 to 50 percent lower in individuals with amyloid-positive brain scans. Additional laboratory testing confirmed that vitronectin directly binds to amyloid-beta molecules, preventing them from joining together into the toxic oligomers believed to damage nerve cells.
Further experiments showed that adding purified vitronectin back into blood samples reduced amyloid-beta oligomer formation in a dose-dependent manner.
The protein also reduced amyloid fibril formation by as much as 68 percent, demonstrating a powerful protective effect against abnormal protein aggregation.
>
This
Medical News report highlights that computer modeling and laboratory binding experiments both confirmed a direct interaction between vitronectin and amyloid-beta, strengthening evidence that the protein is actively involved in controlling these disease-related processes rather than merely serving as an associated biomarker.
Blood Protein Networks May Matter More Than Previously Believed
The researchers also discovered that Alzheimer’s disease is associated with major changes in the overall organization of blood proteins rather than isolated abnormalities. Several proteins involved in immune regulation, inflammation, metabolism and cholesterol transport were altered alongside vitronectin, suggesting that widespread disturbances throughout the bloodstream may influence how easily amyloid proteins become toxic.
The findings also indicate that maintaining a healthy albumin-associated protein network could become a future therapeutic strategy aimed at slowing harmful amyloid formation before significant brain damage develops.
Conclusion
The study provides compelling evidence that vitronectin is far more than an ordinary blood protein. By directly limiting toxic amyloid-beta aggregation while reflecting widespread disturbances in circulating protein networks, vitronectin could become both a promising blood biomarker and a future therapeutic target for identifying and potentially slowing the earliest stages of Alzheimer’s disease before symptoms become severe.
The study findings were published in the peer reviewed International Journal of Molecular Sciences.
https://www.mdpi.com/1422-0067/27/13/5744
For the latest on Alzheimer’s disease, keep on logging to Thailand
Medical News.
Read Also:
https://www.thailandmedical.news/articles/alzheimer,-dementia-
Share
Tweet
Share
